http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
제천전(濟川煎)과 약물(藥物) 가감(加減)이 흰쥐의 사하작용(瀉下作用)에 미치는 영향(影響)
이승희,이상준,박수연,김홍렬,박성규,Lee Seung-Hee,Lee Sang-Jun,Park Soo-Yeon,Kim Hong-Yeoul,Park Seong-Kyu 대한한의학방제학회 2002 大韓韓醫學方劑學會誌 Vol.10 No.1
We have examined the purgative effect of three Jechun-jun formulas in sprague dawley(SD) rat. Three jechun-jun formulas were Jechun-jun(Sample I ) and augmented Jechun-jun(Sample II) and augmented Jechun-jun add rhubarb(sample III ). We examined the amount and the humidity of feces in rat. The experimental animals were devided into four groups. as control group and three Jechun-jun (sample I, II, III). We administerd the water extract of sample I, II, III to rat per oral for 8days long. After every 24hours measured the amount of wet feces from rats in metabolic cage. Humidity rate of feces from rat was at first measure wet feces for 24hours (W) and measure dried feces (W1) and then we consider W-W1 as humidity. High humidity rate means constipation changes into moistening stool. The amount of wet feces and humidity rate of feces in rats were increased in sample I, II, III. Sample I has highest humidity rate of feces. so showed strong moistening effect. Sample II has mild effect in treating constipation. sample III has most amount of wet feces. in conclusion Jechun-jun has an effect of moistening stool. and augmented Jechun-jun add rhubarb has strong purgative effect.
Hong, Il Ki,Kim, Seog Young,Chung, Jin Hwa,Lee, Seung Jin,Oh, Seung Jun,Lee, Sang Ju,Oh, Jungsu,Ryu, Jin-Sook,Kim, Tae Won,Kim, Deog Yoon,Moon, Dae Hyuk Potamitis Press 2014 Anticancer research Vol.34 No.2
<P>We aimed to investigate whether 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) positron emission tomography (PET) can estimate thymidine kinase 1 (TK1) activity after thymidylate synthase (TS) inhibition by 5-fluorouracil (5-FU) in a mouse tumor model.</P>
Case Reports : A primo vessel-Like structure in a dog with inflammatory pseudotumor
( Sung Jin Cho ),( Sun Hwa Hong ),( Sang Jun Han ),( Ok Jin Kim ) 한국가축위생학회 2012 韓國家畜衛生學會誌 Vol.35 No.1
Inflammatory pseudotumor (IPT) is a term defining a mass characterized microscopically by a proliferation of bland mesenchymal spindle cells infiltrated by diffuse mixed inflammatory cells with a predominance of plasma cells and lymphocytes. Here, we show the primo vessel-like structure of the primo-vascular system (PVS) in a dog with IPT. A 6-years old male Mongrel dog was diagnosed with an abnormal mass (diameter 5.5 cm, weight 22 g) near left preputial area. The dog was submitted to the surgical detectomy of the mass. During the surgical operation, we observed primo vessel-like material. After fixations, the masses appeared macroscopically as lipoid-like, firm, white to grey masses, measuring 5×8 cm. Histologically, cellular infiltration into the muscular layers was frequently seen. The mesenchymal proliferation remained the main component of the mass and was composed of myofibroblastic- like spindle cells characterized by globular, irregular nuclei containing open chromatin and a prominent nucleolus. On the basis of the histopathologic lesions, the subcutaneous mass was diagnosed as IPT. Also, we detected a primo vessel-like structures in some areas of the IPT tissues. These were observed as novel thread-like structures and bundle of tubular structures. To our knowledge, this report is the first case of primo vessel-like structure in a dog with IPT.
Hong, Jong Kyu,Bang, Ju Yup,Xu, Guan,Lee, Jun-Hee,Kim, Yeon-Ju,Lee, Ho-Jun,Kim, Han Seong,Kwon, Sang-Mo Dove Medical Press 2015 International journal of nanomedicine Vol.10 No.-
<P>Controlling the thickness of an electrospun nanofibrous scaffold by altering its pore size has been shown to regulate cell behaviors such as cell infiltration into a three-dimensional (3D) scaffold. This is of great importance when manufacturing tissue-engineering scaffolds using an electrospinning process. In this study, we report the development of a novel process whereby additional aluminum foil layers were applied to the accumulated electrospun fibers of an existing aluminum foil collector, effectively reducing the incidence of charge buildup. Using this process, we fabricated an electrospun scaffold with a large pore (pore size >40 μm) while simultaneously controlling the thickness. We demonstrate that the large pore size triggered rapid infiltration (160 μm in 4 hours of cell culture) of individual endothelial progenitor cells (EPCs) and rapid cell colonization after seeding EPC spheroids. We confirmed that the 3D, but not two-dimensional, scaffold structures regulated tubular structure formation by the EPCs. Thus, incorporation of stem cells into a highly porous 3D scaffold with tunable thickness has implications for the regeneration of vascularized thick tissues and cardiac patch development.</P>
Hong, Soon Jun,Jeong, Han Saem,Ahn, Jeong Cheon,Cha, Dong-Hun,Won, Kyung Heon,Kim, Weon,Cho, Sang Kyoon,Kim, Seok-Yeon,Yoo, Byung-Su,Sung, Ki Chul,Rha, Seung-Woon,Shin, Joon-Han,Han, Kyoo Rok,Chung, W Elsevier 2018 Clinical therapeutics Vol.40 No.2
<P><B>Abstract</B></P> <P><B>Purpose</B></P> <P>Combination therapy with ezetimibe and statins is recommended in cases of statin intolerance or insufficiency. The objective of this study was to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus those of rosuvastatin monotherapy in patients with hypercholesterolemia.</P> <P><B>Methods</B></P> <P>I-ROSETTE (Ildong ROSuvastatin & ezETimibe for hypercholesTElolemia) was an 8-week, double-blind, multicenter, Phase III randomized controlled trial conducted at 20 hospitals in the Republic of Korea. Patients with hypercholesterolemia who required medical treatment according to National Cholesterol Education Program Adult Treatment Panel III guidelines were eligible for participation in the study. Patients were randomly assigned to receive ezetimibe 10 mg/rosuvastatin 20 mg, ezetimibe 10 mg/rosuvastatin 10 mg, ezetimibe 10 mg/rosuvastatin 5 mg, rosuvastatin 20 mg, rosuvastatin 10 mg, or rosuvastatin 5 mg in a 1:1:1:1:1:1 ratio. The primary end point was the difference in the mean percent change from baseline in LDL-C level after 8 weeks of treatment between the ezetimibe/rosuvastatin and rosuvastatin treatment groups. All patients were assessed for adverse events (AEs), clinical laboratory data, and vital signs.</P> <P><B>Findings</B></P> <P>Of 396 patients, 389 with efficacy data were analyzed. Baseline characteristics among 6 groups were similar. After 8 weeks of double-blind treatment, the percent changes in adjusted mean LDL-C levels at week 8 compared with baseline values were –57.0% (2.1%) and –44.4% (2.1%) in the total ezetimibe/rosuvastatin and total rosuvastatin groups, respectively (<I>P</I> < 0.001). The LDL-C–lowering efficacy of each of the ezetimibe/rosuvastatin combinations was superior to that of each of the respective doses of rosuvastatin. The mean percent change in LDL-C level in all ezetimibe/rosuvastatin combination groups was >50%. The number of patients who achieved target LDL-C levels at week 8 was significantly greater in the ezetimibe/rosuvastatin group (180 [92.3%] of 195 patients) than in the rosuvastatin monotherapy group (155 [79.9%] of 194 patients) (<I>P</I> < 0.001). There were no significant differences in the incidence of overall AEs, adverse drug reactions, and serious AEs; laboratory findings, including liver function test results and creatinine kinase levels, were comparable between groups.</P> <P><B>Implications</B></P> <P>Fixed-dose combinations of ezetimibe/rosuvastatin significantly improved lipid profiles in patients with hypercholesterolemia compared with rosuvastatin monotherapy. All groups treated with rosuvastatin and ezetimibe reported a decrease in mean LDL-C level >50%. The safety and tolerability of ezetimibe/rosuvastatin therapy were comparable with those of rosuvastatin monotherapy. ClinicalTrials.gov identifier: NCT02749994.</P>
Pyrin Domain (PYD)-containing Inflammasome in Innate Immunity
Hong, Su-Jeong,Park, Sang-Jun,Yu, Je-Wook The Korean Society for Microbiology 2011 Journal of Bacteriology and Virology Vol.41 No.3
Inflammasome is a cytosolic multiprotein complex to activate caspase-1 leading to the subsequent processing of inactive pro-interleukin-1-beta (Pro-IL-$1{\beta}$) into its active interleukin-1 beta (IL-$1{\beta}$) in response to pathogen- or dangerassociated molecular pattern. In recent years, a huge progress has been made to identify inflammasome component as a molecular platform to recruit and activate caspase-1. Nucleotide-binding oligomerization domain-like receptor (NLR) family proteins such as NLRP1, NLRP3 or interleukin-$1{\beta}$-converting enzyme (ICE)-protease activating factor (IPAF) have been first characterized to form inflammasome complex to induce caspase-1 activation. More recently, non-NLR type, pyrin-domain (PYD)-containing proteins such as pyrin or absent in melanoma2 (AIM2) were also proposed to form caspase-1-activating inflammasome machinery with apoptosis-associated speck-like protein containing a CARD (ASC), an essential adaptor molecule. Inflammasome pathways were shown to be crucial for protecting host organisms against diverse pathogen infections, but accumulating evidences also suggest that excessive activation of inflammasome/ caspase-1 might be related to the pathogenesis of inflammation-related diseases. Indeed, mutations in NLRP3 or pyrin are closely associated with autoinflammatory diseases such as familial Mediterranean fever (FMF) syndrome or Muckle-Wells syndrome (MWS), indicating that the regulation of caspase-1 activity by inflammasome is a central process in these hereditary inflammatory disorders. Here, recent advances on the molecular mechanism of caspase-1 activation by PYD-containing inflammasomes are summarized and discussed.